The Chemistry and Cancer Program (CCP) seeks to discover small molecule chemicals capable of either antagonizing or agonizing regulatory pathways relevant to human cancer. Research efforts in the CCP proceed from one of two directions, chemistry-to-biology or biology-to-chemistry. In the former case, the discovery process starts with a novel natural product that is cytotoxic to cancer cells. This molecule, and specific derivatives synthesized by organic chemists, is then subjected to biochemical, genetic or molecular biological studies aimed at resolving its precise mode of action. Alternatively, knowledge of a specific biological pathway relevant to human cancer prompts attempts to identify small chemical antagonists or agonists of the pathway. The latter path is prosecuted by high throughput drug screening, rafional peptidomimetics, or preparation of synthetic analojgs of biological metabolites. In this context, the current scientific program themes are: 1) Identifying the Molecular Targets of Novel Cytotoxic Agents. 2) Biochemical Dissection of Novel. Cancer Cell-Specific Pathways. 3) Smac mimetics and other means of perturbing apoptosis with synthetic chemicals. 4) Regulation and targeting of the hypoxia response pathway with small molecules. The long-term objective of the CCP is to discover """"""""first-in-class"""""""" chemical compounds, some of which may qualify for rigorous pre-clinical development. In doing so, we will provide the scientific expertise and resources from which program- and cancer center-wide translational research can sprout. Therefore, an additional major goal of the CCP is to develop and provide scientific and technical expertise in chemistry, pharmacology and High Throughput screening.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Sw Medical Center Dallas
United States
Zip Code
Eskiocak, Banu; McMillan, Elizabeth A; Mendiratta, Saurabh et al. (2017) Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov 7:832-851
Rutkowski, Joseph M; Pastor, Johanne; Sun, Kai et al. (2017) Adiponectin alters renal calcium and phosphate excretion through regulation of klotho expression. Kidney Int 91:324-337
Singh, Jaspal; Rustagi, Vineeta; Zhang, Shanrong et al. (2017) On-bead combinatorial synthesis and imaging of europium(III)-based paraCEST agents aids in identification of chemical features that enhance CEST sensitivity. Magn Reson Chem 55:747-753
Singh, Dinesh K; Kollipara, Rahul K; Vemireddy, Vamsidara et al. (2017) Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma. Cell Rep 18:961-976
Gu, Yi-Feng; Cohn, Shannon; Christie, Alana et al. (2017) Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade. Cancer Discov 7:900-917
Lee, Ming Y; Sumpter Jr, Rhea; Zou, Zhongju et al. (2017) Peroxisomal protein PEX13 functions in selective autophagy. EMBO Rep 18:48-60
Gao, Boning; Huang, Chunxian; Kernstine, Kemp et al. (2017) Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget 8:11114-11126
Howard, James J; Sturge, Carolyn R; Moustafa, Dina A et al. (2017) Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers. Antimicrob Agents Chemother 61:
Skinner, Celette Sugg; Ahn, Chul; Halm, Ethan A et al. (2017) Recommendation of colorectal cancer testing among primary care patients younger than 50 with elevated risk. Prev Med 102:20-23
Garcia, Sandra; Bisen, Ajit; Yan, Jingsheng et al. (2017) Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. J Thorac Oncol 12:1489-1495

Showing the most recent 10 out of 441 publications